PUBLISHER: TechNavio | PRODUCT CODE: 1916075
PUBLISHER: TechNavio | PRODUCT CODE: 1916075
Global Viral Vector Manufacturing Market 2025-2029
The global viral vector manufacturing market is forecasted to grow by USD 4134.3 mn during 2024-2029, accelerating at a CAGR of 19.3% during the forecast period. The report on the global viral vector manufacturing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanding pipeline and regulatory approval of cell and gene therapies, surge in strategic investments and collaborations to expand manufacturing capacity, technological innovation in vector production and process optimization.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2029 |
| Series Year | 2025-2029 |
| Growth Momentum | Accelerate |
| YOY 2025 | 16.2% |
| CAGR | 19.3% |
| Incremental Value | $4134.3 mn |
Technavio's global viral vector manufacturing market is segmented as below:
By Manufacturing Type
- In-house manufacturing
- Contract manufacturing
By Application
- Genetic disorders
- Infectious disease
- Cancer
- Neurological disorders
- Others
By Type
- Adeno-associated viral (AAV) vectors
- Lentiviral vectors
- Adenoviral vectors
- Others
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- The Netherlands
- Spain
- Russia
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the strategic shift towards in-house manufacturing and hybrid operational models as one of the prime reasons driving the global viral vector manufacturing market growth during the next few years. Also, accelerated adoption of process intensification and automation technologies and diversification of viral and non-viral vector technologies will lead to sizable demand in the market.
The report on the global viral vector manufacturing market covers the following areas:
- Global viral vector manufacturing market sizing
- Global viral vector manufacturing market forecast
- Global viral vector manufacturing market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global viral vector manufacturing market vendors that include AGC Biologics, Aldevron LLC, Andelyn Biosciences, Batavia Biosciences BV, Catalent Inc., Charles River Laboratories, Exothera, FUJIFILM Holdings Corp., Genezen, Lonza Group Ltd., Miltenyi Biotec, Oxford Biomedica Plc, Sigma Aldrich Chemicals Ltd., SK Pharmteco, Takara Bio Inc., Thermo Fisher Scientific Inc., Virovek Inc. Also, the global viral vector manufacturing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Manufacturing Type
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
5 Historic Market Size
- 5.1 Global Viral Vector Manufacturing Market 2019 - 2023
- Historic Market Size - Data Table on Global Viral Vector Manufacturing Market 2019 - 2023 ($ million)
- 5.2 Manufacturing Type segment analysis 2019 - 2023
- Historic Market Size - Manufacturing Type Segment 2019 - 2023 ($ million)
- 5.3 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ million)
- 5.4 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
7 Market Segmentation by Manufacturing Type
- 7.1 Market segments
- 7.2 Comparison by Manufacturing Type
- 7.3 In-house manufacturing - Market size and forecast 2024-2029
- 7.4 Contract manufacturing - Market size and forecast 2024-2029
- 7.5 Market opportunity by Manufacturing Type
- Market opportunity by Manufacturing Type ($ million)
8 Market Segmentation by Application
- 8.1 Market segments
- 8.2 Comparison by Application
- 8.3 Genetic disorders - Market size and forecast 2024-2029
- 8.4 Infectious disease - Market size and forecast 2024-2029
- 8.5 Cancer - Market size and forecast 2024-2029
- 8.6 Neurological disorders - Market size and forecast 2024-2029
- 8.7 Others - Market size and forecast 2024-2029
- 8.8 Market opportunity by Application
- Market opportunity by Application ($ million)
9 Market Segmentation by Type
- 9.1 Market segments
- 9.2 Comparison by Type
- 9.3 Adeno-associated viral (AAV) vectors - Market size and forecast 2024-2029
- 9.4 Lentiviral vectors - Market size and forecast 2024-2029
- 9.5 Adenoviral vectors - Market size and forecast 2024-2029
- 9.6 Others - Market size and forecast 2024-2029
- 9.7 Market opportunity by Type
- Market opportunity by Type ($ million)
10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11.1 Geographic segmentation
- 11.2 Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- 11.3.1 US - Market size and forecast 2024-2029
- 11.3.2 Canada - Market size and forecast 2024-2029
- 11.3.3 Mexico - Market size and forecast 2024-2029
- 11.4 Europe - Market size and forecast 2024-2029
- 11.4.1 Germany - Market size and forecast 2024-2029
- 11.4.2 UK - Market size and forecast 2024-2029
- 11.4.3 France - Market size and forecast 2024-2029
- 11.4.4 Italy - Market size and forecast 2024-2029
- 11.4.5 The Netherlands - Market size and forecast 2024-2029
- 11.4.6 Spain - Market size and forecast 2024-2029
- 11.4.7 Russia - Market size and forecast 2024-2029
- 11.5 Asia - Market size and forecast 2024-2029
- 11.5.1 China - Market size and forecast 2024-2029
- 11.5.2 Japan - Market size and forecast 2024-2029
- 11.5.3 India - Market size and forecast 2024-2029
- 11.5.4 South Korea - Market size and forecast 2024-2029
- 11.5.5 Indonesia - Market size and forecast 2024-2029
- 11.5.6 Thailand - Market size and forecast 2024-2029
- 11.5.7 Singapore - Market size and forecast 2024-2029
- 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
- 11.6.1 Australia - Market size and forecast 2024-2029
- 11.6.2 UAE - Market size and forecast 2024-2029
- 11.6.3 Brazil - Market size and forecast 2024-2029
- 11.6.4 South Africa - Market size and forecast 2024-2029
- 11.6.5 Saudi Arabia - Market size and forecast 2024-2029
- 11.6.6 Turkey - Market size and forecast 2024-2029
- 11.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Expanding pipeline and regulatory approval of cell and gene therapies
- Surge in strategic investments and collaborations to expand manufacturing capacity
- Technological innovation in vector production and process optimization
- 12.2 Market challenges
- Complex manufacturing processes and persistent scalability issues
- Prohibitively high cost of goods and stringent reimbursement landscapes
- Evolving and stringent regulatory frameworks for product characterization and safety
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Strategic shift towards in-house manufacturing and hybrid operational models
- Accelerated adoption of process intensification and automation technologies
- Diversification of viral and non-viral vector technologies
13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14.1 Companies profiled
- Companies covered
- 14.2 Company ranking index
- Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 AGC Biologics
- AGC Biologics - Overview
- AGC Biologics - Product / Service
- AGC Biologics - Key offerings
- SWOT
- 14.5 Aldevron LLC
- Aldevron LLC - Overview
- Aldevron LLC - Product / Service
- Aldevron LLC - Key offerings
- SWOT
- 14.6 Batavia Biosciences BV
- Batavia Biosciences BV - Overview
- Batavia Biosciences BV - Product / Service
- Batavia Biosciences BV - Key offerings
- SWOT
- 14.7 Catalent Inc.
- Catalent Inc. - Overview
- Catalent Inc. - Business segments
- Catalent Inc. - Key offerings
- Catalent Inc. - Segment focus
- SWOT
- 14.8 Charles River Laboratories
- Charles River Laboratories - Overview
- Charles River Laboratories - Business segments
- Charles River Laboratories - Key offerings
- Charles River Laboratories - Segment focus
- SWOT
- 14.9 FUJIFILM Holdings Corp.
- FUJIFILM Holdings Corp. - Overview
- FUJIFILM Holdings Corp. - Business segments
- FUJIFILM Holdings Corp. - Key news
- FUJIFILM Holdings Corp. - Key offerings
- FUJIFILM Holdings Corp. - Segment focus
- SWOT
- 14.10 Genezen
- Genezen - Overview
- Genezen - Product / Service
- Genezen - Key offerings
- SWOT
- 14.11 Lonza Group Ltd.
- Lonza Group Ltd. - Overview
- Lonza Group Ltd. - Business segments
- Lonza Group Ltd. - Key news
- Lonza Group Ltd. - Key offerings
- Lonza Group Ltd. - Segment focus
- SWOT
- 14.12 Miltenyi Biotec
- Miltenyi Biotec - Overview
- Miltenyi Biotec - Product / Service
- Miltenyi Biotec - Key offerings
- SWOT
- 14.13 Oxford Biomedica Plc
- Oxford Biomedica Plc - Overview
- Oxford Biomedica Plc - Product / Service
- Oxford Biomedica Plc - Key offerings
- SWOT
- 14.14 Sigma Aldrich Chemicals Ltd.
- Sigma Aldrich Chemicals Ltd. - Overview
- Sigma Aldrich Chemicals Ltd. - Product / Service
- Sigma Aldrich Chemicals Ltd. - Key offerings
- SWOT
- 14.15 SK Pharmteco
- SK Pharmteco - Overview
- SK Pharmteco - Product / Service
- SK Pharmteco - Key offerings
- SWOT
- 14.16 Takara Bio Inc.
- Takara Bio Inc. - Overview
- Takara Bio Inc. - Product / Service
- Takara Bio Inc. - Key offerings
- SWOT
- 14.17 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
- 14.18 Virovek Inc
- Virovek Inc - Overview
- Virovek Inc - Product / Service
- Virovek Inc - Key offerings
- SWOT
15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- Research methodology
- 15.5 Data procurement
- Information sources
- 15.6 Data validation
- Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
- List of abbreviations
